The global endoscopy procedures market is estimated to grow at a CAGR of 7.0% from 2022 to 2030. Key factors driving the market growth are growing preference for minimally invasive surgeries and increasing prevalence of cancer are the key factors driving the market. However, the risks of infections associated with endoscopic procedures hamper the market growth.

The global cerebrospinal fluid management market is estimated to grow at a CAGR of 5.3% from 2022 to 2030. Key factors driving the market growth are increasing incidences of CSF leak and growing developments for CSF management products. However, the risk associated with CSF shunts hinders the market growth.

The Global bariatric surgeries market is estimated to grow at a CAGR of 15.9% from 2022 to 2030. Key factors driving the market growth are the increasing prevalence of obesity and growing demand for minimally invasive surgeries are driving the market growth. However, the stringent regulatory policies and increase in safety concerns restrain the market growth.

The automated external defibrillators market is estimated to grow at a CAGR of 4.5% from 2020 to 2030. Key factors driving the market growth are increasing prevalence of cardiovascular diseases and rising training and awareness programs on automated external defibrillators. Whereas performance issues related to automated external defibrillators is hindering the market growth.

The global aesthetic lasers market is estimated to grow at a CAGR of 12.3% from 2022 to 2030. Key factors driving the market growth are growing adoption of non-invasive aesthetic procedures and increasing prevalence of skin disorders along with growing awareness about beauty devices. However, risks and complications associated with procedures and stringent safety regulations hinders the market growth.

As per the scope of the report, the tonometer is an instrument used to determine intraocular pressure or the pressure of the fluid within the eye. Tonometry is a diagnostic test primarily used to detect glaucoma.

The global fundus camera market is estimated to grow at a CAGR of 7.9% from 2022 to 2030. Key factors driving the market growth are increase in diabetic retinopathy screening procedures and launches of innovative products. However, incorrect clinical diagnosis due to distorted fundus photography hinders the market growth.

全球仅福他替尼一款SYK抑制剂获批上市，索乐匹尼布进展全球第二/中国第一，激酶选择性更高，脱靶毒性更小。Syk在免疫细胞中广泛表达，是B细胞激活信号转导过程中重要的非受体酪氨酸激酶。目前适应症探索主要集中在血液肿瘤、自身免疫性疾病两大方向。Syk可同时作用于B细胞和巨噬细胞，通过完全不同的作用机制，从根本解决ITP问题。全球研发格局方面，目前全球范围仅有福他替尼这一款SYK抑制剂获批上市，用于治疗免疫性血小板减少症；和黄医药的索乐匹尼布针对二线原发性免疫血小板减少症的NDA已于24年1月获CDE受理，目前进展全球第二/中国第一。

对于尚未有产品商业化收入的科创板Biotech，“现金等/研发费用“比值中位数约为4.9；非科创板的A股药企基本具备较稳定的经营现金流量净额，“现金等/研发费用“比值中位数约为4.4，“经营现金流量额/研发费用”比值中位数约为1.8。部分Biotech的技术服务收入、授权收入等可以贡献较多现金，比如百利天恒BL-B01D1于2023年底 和BMS的重磅合作，将获得8亿美元的首付款和最高5亿美元的或有近期付款。还有部分Biotech处于产品放量元年/初期，2024年产品收入将有明显增长从而弥补现金流，比如迪哲医药的舒沃替尼2023年8月获批上市。